FGF2 and neoplasm: In addition, gefitinib has been suggested to decrease the expression levels of proangiogenic factors, such as vascular endothelial growth factor and basic fibroblast growth factor in tumour cells, to inhibit migration and tube formation of endothelial cells and to reduce the invasive potential of tumour cells (Ciardiello et al, 2001; Bianco et al, 2002; Fujimura et al, 2002; Hirata et al, 2002).